ITGA2B
Integrin alpha-IIb
As of the edition of 20 October 2026, ITGA2B (integrin alpha-IIb, UniProt P08514) has 4 drugs tested at it and 5 companies on the list, 1 on route A and 3 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P08514
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 80
- Disease areas
- Heart and blood vessels; Nervous system; Infections; Lungs and airways; Blood and lymph; Hormones; Inherited and neonatal; Nutrition and metabolism
- Registered trials of its drugs
- 74
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 2 |
| Went quiet | 1 |
| Status not established | 1 |
| Total | 4 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Tirofiban | Marketed | Phase 4 | none listed |
| Eptifibatide | Marketed | Phase 4 | none listed |
| Lefradafiban | Went quiet | Phase 1 | none listed |
| Zalunfiban | Status not established | Phase 3 | none listed |
4 of 4 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Route B | 3 |
| Undetermined | 1 |
| Total on the list | 5 |
| Company | Route |
|---|---|
| Merck & Co. | Route B |
| Medicure | Route B |
| Cipher Pharmaceuticals | Route B |
The other 2 companies at ITGA2B
In the product5 companies in all; 2 are not named here, and no score is.
See the 5 companies at ITGA2B, ranked, with the facts behind eachRequest access. Nothing is shown until you do.